Back to search
FDAFDA · Food and drugs·Recall number D-1234-2020

Simvastatin Tablets, USP 40mg 90-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 65862-053-90

Published April 22, 2020 · Recall initiated: March 18, 2020

Summary

FDA records drug Class II recall D-1234-2020, published April 22, 2020 and initiated March 18, 2020. Recalling firm: Aurobindo Pharma USA Inc.; Status: Terminated; Reported quantity: 26976 units; Lot: Lot #: 05319004A1, Exp. Date 03/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

What to do

Voluntary: Firm initiated · Letter

Get an email if SIMVASTATIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
SIMVASTATIN
Manufacturer
Aurobindo Pharma USA Inc.
Distributor
Nationwide within the United States
Lot
Lot #: 05319004A1, Exp. Date 03/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Simvastatin Tablets, USP 40mg 90-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 65862-053-90 recalled?

Yes. FDA published recall D-1234-2020 on April 22, 2020. Reported hazard: CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: SIMVASTATIN.